Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 May 2024 | Story ANTHONY MTHEMBU | Photo Supplied
Ibrahim Mahama
Contemporary artist Ibrahim Mahama engaging with students during his visit to the Department of Fine Arts at the University of the Free State (UFS).

Ghanaian contemporary artist, Ibrahim Mahama, visited the Department of Fine Arts at the University of the Free State (UFS) to share insights with staff and students during his stay in the country.

Dr Adelheid Von Maltitz, Senior Lecturer in the Department of Fine Arts at the UFS, highlighted the significance of Mahama’s visit which took place from 21 to 28 March 2024, marking the first instance of such interaction between a Fine Arts department in South Africa and Mahama. She remarked, “It is truly astounding that a person of his calibre dedicated time to focus on our department, and I believe this has catalysed a positive shift within our department.”

Mahama’s impactful presence at UFS

Dr Von Maltitz emphasised that Mahama’s visit aimed to offer staff and students a glimpse into his artistic process and mindset. During his time at the UFS, Mahama, who was virtually overseeing his latest recent large-scale artwork titled Purple Hibiscus, which involved wrapping the Barbican Centre in London, engaged extensively with staff and students from the department about their research. He shared insights into his creative journey, presented select works, and conducted critique sessions with fourth year and postgraduate students, among other activities. Dr Von Maltitz believes this interaction, particularly with students, has significantly bolstered their confidence as aspiring artists, preparing them for professional endeavours.

Broader implications and future prospects

Mahama’s visit not only energised the department’s academic environment but also holds broader implications. Dr Von Maltitz asserted that it will solidify the department’s identity nationally and create avenues for students to pursue residencies in countries like Ghana. Therefore, maintaining a fruitful relationship with Mahama remains a priority for the department.

Reflecting on the visit Dr Von Maltitz concluded, ‘’the key takeaway, especially for the students, was witnessing the potential of their works within the broader South African and international contexts. “ 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept